[1]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,(10):126-128.[doi:10.3969/j.issn.1006-1959.2018.10.041]
 LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,(10):126-128.[doi:10.3969/j.issn.1006-1959.2018.10.041]
点击复制

盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年10期
页码:
126-128
栏目:
药物与临床
出版日期:
2018-05-15

文章信息/Info

Title:
Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure
文章编号:
1006-1959(2018)10-0126-03
作者:
李 铎王建华
佳木斯市中心医院心内科,黑龙江 佳木斯 154002
Author(s):
LI DuoWANG Jian-hua
Department of Cardiology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China
关键词:
冠心病心力衰竭盐酸曲美他嗪片氧化应激心肌功能
Keywords:
Key words:Coronary heart diseaseHeart failureTrimetazidine hydrochloride tabletsOxidative stressMyocardial function
分类号:
R541.4;R541.6
DOI:
10.3969/j.issn.1006-1959.2018.10.041
文献标志码:
A
摘要:
目的 探讨盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者的氧化应激、心肌功能的影响。方法 选择我院心内科2016年6月~2017年6月80例冠心病伴心力衰竭患者,按照随机数字表法分为传统组与辅助组,每组40例,传统组患者给予常规治疗,辅助组患者在常规治疗基础上给予盐酸曲美他嗪片辅助治疗,对比两组患者治疗后LVEF、SO、LVESD、LVEDD、MDA水平。结果 辅助组患者治疗后LVEF(58.1±7.5)%、SOD(120.2±15.8)U/ml较传统组(51.2±6.5)%、(84.2±12.4)U/ml升高,LVESD(44.8±4.2)mm、LVEDD(31.2±3.3)mm、MDA(6.2±1.3)μmol/L较传统组(48.2±4.6)mm、(35.4±3.5)mm、(8.6±1.5)μmol/L降低,差异有统计学意义(P<0.05)。结论 盐酸曲美他嗪片辅助治疗冠心病伴心力衰竭患者可改善患者氧化应激状况,提升患者心肌功能。
Abstract:
Abstract:Objective To investigate the effects of adjuvant trimetazole hydrochloride on oxidative stress and myocardial function in patients with coronary heart disease complicated with heart failure.Methods From June 2016 to June 2017,80 patients with coronary heart disease complicated with heart failure in our hospital were divided into two groups:the traditional group(40 cases)and the auxiliary group(40 cases).The patients in the traditional group were treated with routine therapy.The patients in the adjuvant group were given trimetazidine hydrochloride on the basis of routine treatment,the levels of LVEF,SO,LVESD,LVEDD and MDA were compared between the two groups after treatment.Results After treatment,LVEF(58.1±7.5)%and SOD(120.2±15.8)U/ml in the adjuvant group were higher than those in the traditional group(51.2±6.5)%and(84.2±12.4)U/ml,and the LVESD was(44.8±4.2)mm. LVEDD(31.2±3.3)mm,MDA(6.2±1.3)μmol/L decreased compared with the traditional group(48.2±4.6)mm,(35.4±3.5)mm,(8.6±1.5) μmol/L,the difference was statistically significant(P<0.05).Conclusion Trimetazidine hydrochloride tablets adjuvant treatment of coronary heart disease complicated with heart failure can improve the patient's oxidative stress,improve myocardial function.

参考文献/References:

[1]杨茂森.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效分析[J].医学信息,2015,28(47):362-363.
[2]周旋.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者82例临床研究[J].医学信息,2015,28(46):391-392.
[3]孙小军,卢京.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效观察[J].中国医院用药评价与分析,2015,15(3):312-314.
[4]李平,李佑美.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血浆BNP影响及疗效观察[J].海南医学院学报,2016,22(2):126-128.
[5]卢竞前,杨锋,张洲,等.曲美他嗪对冠心病慢性收缩性心力衰竭患者心功能及N末端B型利钠肽原的影响[J].中国老年学杂志,2016,36(16):3963-3965.
[6]朱潮潘,杨泽福,庄奕娜,等.曲美他嗪对冠心病合并心力衰竭患者心率变异性的影响[J].山东医药,2016,56(30):79-81.
[7]郭峰,周乃珍.曲美他嗪片治疗冠心病心力衰竭的临床研究[J].中国临床药理学杂志,2017,33(15):1406-1408.
[8]姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[9]陈玲,吕湛,何文凤,等.曲美他嗪对冠心病心力衰竭患者心肌功能与相关免疫指标的影响[J].川北医学院学报,2016,31(4):509-512.
[10]韦耀.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效分析[J].实用临床医药杂志,2017,21(15):183-184.
[11]吕云,潘娅萍,高彦,等.盐酸曲美他嗪对冠心病合并心力衰竭患者N端脑钠肽前体、心功能及远期预后的影响[J].医学综述,2015,21(16):3032-3033,3034.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
 GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,(10):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
 YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,(10):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[3]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
 ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,(10):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[4]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
 ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,(10):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[5]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
 ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,(10):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[6]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
 XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,(10):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[7]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
 WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,(10):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[8]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
 CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,(10):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[9]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
 HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,(10):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[10]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
 MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[11]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
 HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,(10):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[12]纪东华.曲美他嗪治疗老年冠心病心力衰竭的疗效及其对患者 炎症因子的影响[J].医学信息,2019,(13):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]
 JI Dong-hua.Efficacy of Trimetazidine in the Treatment of Elderly Patients with Coronary Heart Disease and Its Effect on Inflammatory Factors[J].Medical Information,2019,(10):141.[doi:10.3969/j.issn.1006-1959.2019.13.043]

更新日期/Last Update: 2018-05-15